New method predicts COVID-19 severity, could help with hospital triage

During the height of the pandemic, some hospitals were overwhelmed with patients seeking treatment for COVID-19. This situation could happen again during future outbreaks, especially with SARS-CoV-2 variants of concern on the rise. Now, researchers reporting in ACS’ Analytical Chemistry…

New theory suggests blood immune and clotting components could contribute to psychosis

A scientific review has found evidence that a disruption in blood clotting and the first line immune system could be contributing factors in the development of psychosis. The article, a joint collaborative effort by researchers at RCSI University of Medicine…

Microscopic CCTV reveals secrets of malaria invasion

State-of-the-art video microscopy has enabled researchers at WEHI, Australia, to see the molecular details of how malaria parasites invade red blood cells – a key step in the disease. The researchers used a custom-built lattice light sheet microscope – the…

CHOP Researchers Develop Proof-of-Concept Treatment that Elevates Both Adult and Fetal Hemoglobin

Researchers at Children’s Hospital of Philadelphia (CHOP) have developed a proof-of-concept treatment for blood disorders like sickle cell disease and beta-thalassemia that could raise hemoglobin levels by activating production of both fetal and adult hemoglobin. Using a viral vector engineered to reactivate fetal hemoglobin production, suppress mutant hemoglobin, and supply functional adult hemoglobin, the researchers developed an approach that could produce more hemoglobin through a single vector. The results were published in Haematologica.

Innovative technologies to develop cancer and virus biomarkers

Politecnico di Torino’s ANFIBIO project will develop a set of technologies and advanced sensors to detect and quantify cancer and viral bio-markers in bodily fluids, making simpler, faster and more economical the diagnosis of many diseases

A review on the current updates in the field of gastroenterology and hepatology

Knowledge in medicine is a very dynamic process due to the continuing progress in this field. New developments influence research, but also the clinical practice. Hence the continuous need for improvement in the field in which we work is required.…

Vitamin B6 deficiency enhances the noradrenergic system, leading to behavioral deficits

Schizophrenia is a heterogeneous psychiatric disorder characterized by positive symptoms such as hallucinations and delusions, negative symptoms such as apathy and lack of emotion, and cognitive impairment. We have reported that VB6 (pyridoxal) levels in peripheral blood of a subpopulation…

An illuminating possibility for stroke treatment: Nano-photosynthesis

Blocked blood vessels in the brains of stroke patients prevent oxygen-rich blood from getting to cells, causing severe damage. Plants and some microbes produce oxygen through photosynthesis. What if there was a way to make photosynthesis happen in the brains…

Emergency physicians first to safely treat vaccine-induced blood clot with heparin alternative

WASHINGTON, DC — A new case report, detailed in Annals of Emergency Medicine , is the first known case of a patient with VITT (vaccine-induced thrombotic thrombocytopenia) treated with a heparin alternative following the Centers for Disease Control and Prevention…

ACS Spring 2021 press conference schedule

Watch live and recorded press conferences at http://www. acs. org/ acsspring2021conferences . Press conferences will be held Monday, April 5, through Friday, April 16, 2021. Below is the schedule, which will be updated as needed. ALL TOPICS ARE STRICTLY EMBARGOED…

CHOP-led Research Study Identifies Key Target in Treatment-Resistant Hemophilia A

Researchers at Children’s Hospital of Philadelphia (CHOP) have identified a key target that may be responsible for treatment failure in about 30% of patients with hemophilia A. The target, known as B cell activating factor (BAFF), appears to promote antibodies against and inhibitors of the missing blood clotting factor that is given to these patients to control their bleeding episodes. The findings, published in the Journal of Clinical Investigation, raise the possibility of using anti-BAFF therapies, potentially in combination with immune tolerance therapies, to tame the immune response in some patients with severe hemophilia A.

FDA approvals strengthen Octapharma USA pediatric critical care product portfolio

Octaplas™ and fibryga® receive new product labeling following FDA’s approval of BLA supplements to update therapy research; FDA expands fibryga® indication to include treatment of children under 12 years of age